skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Dioscin inhibits osteoclast differentiation and bone resorption though down-regulating the Akt signaling cascades

Abstract

Highlights: •A natural-derived compound, dioscin, suppresses osteoclast formation and bone resorption. •Dioscin inhibits osteolytic bone loss in vivo. •Dioscin impairs the Akt signaling cascades pathways during osteoclastogenesis. •Dioscin have therapeutic value in treating osteoclast-related diseases. -- Abstract: Bone resorption is the unique function of osteoclasts (OCs) and is critical for both bone homeostasis and pathologic bone diseases including osteoporosis, rheumatoid arthritis and tumor bone metastasis. Thus, searching for natural compounds that may suppress osteoclast formation and/or function is promising for the treatment of osteoclast-related diseases. In this study, we for the first time demonstrated that dioscin suppressed RANKL-mediated osteoclast differentiation and bone resorption in vitro in a dose-dependent manner. The suppressive effect of dioscin is supported by the reduced expression of osteoclast-specific markers. Further molecular analysis revealed that dioscin abrogated AKT phosphorylation, which subsequently impaired RANKL-induced nuclear factor-kappaB (NF-κB) signaling pathway and inhibited NFATc1 transcriptional activity. Moreover, in vivo studies further verified the bone protection activity of dioscin in osteolytic animal model. Together our data demonstrate that dioscin suppressed RANKL-induced osteoclast formation and function through Akt signaling cascades. Therefore, dioscin is a potential natural agent for the treatment of osteoclast-related diseases.

Authors:
; ; ;  [1];  [1];  [1];  [2]; ;  [1];  [1];  [1]
  1. Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedics, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai (China)
  2. Department of Orthopaedic Surgery, The Central Hospital of Xuzhou, Affiliated Hospital of Medical Collage of Southeast University, Xuzhou (China)
Publication Date:
OSTI Identifier:
22242270
Resource Type:
Journal Article
Journal Name:
Biochemical and Biophysical Research Communications
Additional Journal Information:
Journal Volume: 443; Journal Issue: 2; Other Information: Copyright (c) 2013 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); Journal ID: ISSN 0006-291X
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES; ANIMALS; HOMEOSTASIS; IN VITRO; IN VIVO; METASTASES; NEOPLASMS; OSTEOPOROSIS; PHOSPHORYLATION; RHEUMATIC DISEASES; SKELETON

Citation Formats

Qu, Xinhua, Zhai, Zanjing, Liu, Xuqiang, Li, Haowei, Ouyang, Zhengxiao, Department of Orthopaedics, Hunan Provincial Tumor Hospital and Tumor Hospital of Xiangya School of Medicine, Central South University, Changsha, Wu, Chuanlong, Liu, Guangwang, Fan, Qiming, Tang, Tingting, Qin, An, and Dai, Kerong. Dioscin inhibits osteoclast differentiation and bone resorption though down-regulating the Akt signaling cascades. United States: N. p., 2014. Web. doi:10.1016/J.BBRC.2013.12.029.
Qu, Xinhua, Zhai, Zanjing, Liu, Xuqiang, Li, Haowei, Ouyang, Zhengxiao, Department of Orthopaedics, Hunan Provincial Tumor Hospital and Tumor Hospital of Xiangya School of Medicine, Central South University, Changsha, Wu, Chuanlong, Liu, Guangwang, Fan, Qiming, Tang, Tingting, Qin, An, & Dai, Kerong. Dioscin inhibits osteoclast differentiation and bone resorption though down-regulating the Akt signaling cascades. United States. https://doi.org/10.1016/J.BBRC.2013.12.029
Qu, Xinhua, Zhai, Zanjing, Liu, Xuqiang, Li, Haowei, Ouyang, Zhengxiao, Department of Orthopaedics, Hunan Provincial Tumor Hospital and Tumor Hospital of Xiangya School of Medicine, Central South University, Changsha, Wu, Chuanlong, Liu, Guangwang, Fan, Qiming, Tang, Tingting, Qin, An, and Dai, Kerong. 2014. "Dioscin inhibits osteoclast differentiation and bone resorption though down-regulating the Akt signaling cascades". United States. https://doi.org/10.1016/J.BBRC.2013.12.029.
@article{osti_22242270,
title = {Dioscin inhibits osteoclast differentiation and bone resorption though down-regulating the Akt signaling cascades},
author = {Qu, Xinhua and Zhai, Zanjing and Liu, Xuqiang and Li, Haowei and Ouyang, Zhengxiao and Department of Orthopaedics, Hunan Provincial Tumor Hospital and Tumor Hospital of Xiangya School of Medicine, Central South University, Changsha and Wu, Chuanlong and Liu, Guangwang and Fan, Qiming and Tang, Tingting and Qin, An and Dai, Kerong},
abstractNote = {Highlights: •A natural-derived compound, dioscin, suppresses osteoclast formation and bone resorption. •Dioscin inhibits osteolytic bone loss in vivo. •Dioscin impairs the Akt signaling cascades pathways during osteoclastogenesis. •Dioscin have therapeutic value in treating osteoclast-related diseases. -- Abstract: Bone resorption is the unique function of osteoclasts (OCs) and is critical for both bone homeostasis and pathologic bone diseases including osteoporosis, rheumatoid arthritis and tumor bone metastasis. Thus, searching for natural compounds that may suppress osteoclast formation and/or function is promising for the treatment of osteoclast-related diseases. In this study, we for the first time demonstrated that dioscin suppressed RANKL-mediated osteoclast differentiation and bone resorption in vitro in a dose-dependent manner. The suppressive effect of dioscin is supported by the reduced expression of osteoclast-specific markers. Further molecular analysis revealed that dioscin abrogated AKT phosphorylation, which subsequently impaired RANKL-induced nuclear factor-kappaB (NF-κB) signaling pathway and inhibited NFATc1 transcriptional activity. Moreover, in vivo studies further verified the bone protection activity of dioscin in osteolytic animal model. Together our data demonstrate that dioscin suppressed RANKL-induced osteoclast formation and function through Akt signaling cascades. Therefore, dioscin is a potential natural agent for the treatment of osteoclast-related diseases.},
doi = {10.1016/J.BBRC.2013.12.029},
url = {https://www.osti.gov/biblio/22242270}, journal = {Biochemical and Biophysical Research Communications},
issn = {0006-291X},
number = 2,
volume = 443,
place = {United States},
year = {Fri Jan 10 00:00:00 EST 2014},
month = {Fri Jan 10 00:00:00 EST 2014}
}